Author: Thiru

On 5 March 2013, the Government of India made the following intervention at the TRIPS Council under agenda item 11, request for an extension of the transitional period under Article 66.1 of the TRIPS Agreement. In their intervention, India unequivocally supported the duly motivated requested submitted by Haiti on behalf of the LDC Group on 5 November 2012 (IP/C/W/583).

India asserted that the “no roll back provision” of the 2005 extension had no place in the TRIPS Agreement and noted that

Continue Reading →

On 5 March 2013, the Government of India delivered the following statement at the TRIPS Council on agenda item 13, Intellectual Property and Innovation: Small and Medium-Sized Enterprises, a standalone item tabled by Chile, Chinese Taipei, the Republic of Korea and the United States of America.

We thank the delegations of Chinese Taipei, Korea, the United States and others for tabling an agenda item on “Intellectual Property and Innovation: Small and medium Sized Enterprises” which we understand is a standalone item.

Continue Reading →

On 26 February 2013, one week before the WTO TRIPS Council (5-6 March 2013) meets to consider the LDC Group’s request (IP/C/W/583) for an extension of the transitional period under Article 66.1 of the TRIPS Agreement, UNDP and Continue Reading →

The following statement was delivered at the 19th session of the WIPO Standing Committee on the Law Of Patents (SCP) after presentations by the secretariats of WIPO, WHO and WTO on the trilateral report.

26 February 2013

Continue Reading →

The following WTO airgram WTO/AIR/4075/REV.1 (22 February 2013) contains the agenda for the upcoming WTO Council for TRIPS meeting to be held in Geneva from Tuesday, 5 March 2013 to Wednesday, 6 March 2013. The March 2013 session of the TRIPS Council will discuss the LDC Group’s request (IP/C/W/583) for an extension of the transitional period under Article 66.1 of the TRIPS Agreement under agenda item 11. Continue Reading →

On 17 October 2012, the State Intellectual Property Office of China submitted the following comments to the Electronic Forum of WIPO’s Standing Committee on the Law of Patents (SCP) in relation to the future work of the Committee. The written submission focused on: 1) Exceptions and Limitations to Patent Rights, 2. Quality of Patents and 3. Patents and Health. These points were encapsulated in China’s general intervention today.

[English translation by WIPO]
Continue Reading →

The 19th session of the WIPO Standing Committee on the Law of Patents (SCP) meets in Geneva from 25 February 2013 to 28 February 2013. The 18th session of the SCP ended on a contentions note as WIPO member states could not agree upon the future work of the Committee. In fact, SCP 19 was initially scheduled for November 2012 but was delayed till February 2013 as WIPO’s membership thought informal discussions were required to produce a successful outcome for the future work of the patent committee.

Continue Reading →

Attached below is the version of the negotiating text from 20 February 2013. It includes several new or edited footnotes. We expect the WIPO Special Session of the Standing Committee on Copyright and Related Rights (SCCR) to discuss the new text at the plenary which is scheduled to commence at 10, Wednesday, 21 February 2013.

Footnote 10 is placed within Article E of the draft treaty text on “Importation of Accessible Format Copies” which states

Continue Reading →

On 28 January 2013, the following question tabled by MEP Franziska Keller (Verts/ALE) to the European Union on the EU’s position on extension of WTO TRIPS Agreement transition period for Least Developed Countries was made available. Continue Reading →

As mentioned in a previous piece, the trilateral report by the secretariats of the World Health Organization (WHO), the World Intellectual Property Organization (WIPO) and the World Trade Organization (WTO), Promoting Access to Medical Technologies and Innovation: Intersections between public health, intellectual property and trade, covers a lot of ground including but not limited to: 1) the global burden of disease and global health risks, 2) health and human rights, 3) access to essential medicines: an indicator for the fulfillment of the right to Continue Reading →